（来源：中工网） 河南日报客户端记者 王嘉译 走进打虎亭村卫生所，记者的目光被诊桌上的一沓处方笺吸引。 纸已泛黄，边角卷起，但每一张都写着两个字——免费。最早的一张，落款是2001年，也是她正式加入 村医队伍的第一年。 河南省郑州市新密市牛店镇打虎亭村，常住人口2064人，老人多，孩子多。45岁的村医付文娜在这里干 了25年，是村民口中"比亲闺女还亲"的付医生。 25年里，她开出的"免费处方"有多少张？她没数过。 "数它干啥？"她笑笑，"看病又不看日子。" 记者决定，帮她算算这笔"账"。 临近春节，村里年味渐浓。付文娜背着药箱出了门。她要去的头一户，是张周爷家。 推开虚掩的木门，老人正坐在灶台边。看见付文娜，连忙站起来，语气里满是欣喜："文娜来了！" "周爷，坐着坐着，别忙活。"付文娜快步上前，轻轻按住老人的肩膀，熟练地从药箱里拿出血压 计，"今儿感觉咋样？头还晕不晕？上次给你拿的药，吃完了没？" 量血压、听心肺、问饮食、查精神，一套流程下来，付文娜一丝不苟。随后，她从药箱里取出几盒常用 药，轻轻放进老人床头的抽屉里，反复叮嘱："这药得按时吃，一天一次，一次一粒，千万别漏服，也 别多吃。" 记者在旁边压低声音 ...

走进打虎亭村卫生所，记者的目光被诊桌上的一沓处方笺吸引。 纸已泛黄，边角卷起，但每一张都写着两个字——免费。最早的一张，落款是2001年，也是她正式加入 村医队伍的第一年。 河南省郑州市新密市牛店镇打虎亭村，常住人口2064人，老人多，孩子多。45岁的村医付文娜在这里干 了25年，是村民口中"比亲闺女还亲"的付医生。 25年里，她开出的"免费处方"有多少张？她没数过。 "数它干啥？"她笑笑，"看病又不看日子。" 记者决定，帮她算算这笔"账"。 第一本账："守初心"的健康账 临近春节，村里年味渐浓。付文娜背着药箱出了门。她要去的头一户，是张周爷家。 推开虚掩的木门，老人正坐在灶台边。看见付文娜，连忙站起来，语气里满是欣喜："文娜来了！" "周爷，坐着坐着，别忙活。"付文娜快步上前，轻轻按住老人的肩膀，熟练地从药箱里拿出血压 计，"今儿感觉咋样？头还晕不晕？上次给你拿的药，吃完了没？" 量血压、听心肺、问饮食、查精神，一套流程下来，付文娜一丝不苟。随后，她从药箱里取出几盒常用 药，轻轻放进老人床头的抽屉里，反复叮嘱："这药得按时吃，一天一次，一次一粒，千万别漏服，也 别多吃。" 记者在旁边压低声音问："这药……收 ...

Core Insights - The integration of artificial intelligence in grassroots healthcare is seen as a new pathway to enhance the construction of county-level medical communities and address capability shortcomings [1][2] Group 1: AI Platform Launch - The launch of the AI-assisted diagnostic platform in Fengkai County, Guangdong, marks the establishment of the first county-level AI healthcare platform in the province, aimed at improving access to quality medical resources [1] - The platform will connect 19 county hospitals and township health centers, creating a model for "smart healthcare" that can be quantified, replicated, and promoted across the province and nation [1][2] Group 2: Data Sharing and Integration - The platform focuses on building a "data sharing hub" to connect hospitals and grassroots testing and pathology information systems, enhancing regional medical service capabilities [2] - Gold Domain Medical, as a co-builder of the regional testing and pathology center, is integrating medical data from county and township institutions into a centralized management platform [2] Group 3: AI Applications in Healthcare - The platform will utilize Gold Domain Medical's proprietary AI models and applications to embed intelligent features into hospital workflows, providing clinical doctors with tools for report interpretation, project evaluation, and medication assistance [3] - The integration of AI tools aims to significantly enhance the convenience of diagnosis and treatment processes for healthcare providers [3] Group 4: Strategic Goals and Future Plans - The establishment of the AI-assisted diagnostic platform is a key initiative for Fengkai County to implement the "Healthy China" strategy and the "Hundred Counties, Thousand Towns, and Ten Thousand Villages" project [3] - Future plans include the creation of a "Gold Domain-Fengkai Medical AI Research Training Center" to enhance the understanding and application of AI tools among regional medical personnel [3]

Group 1 - The core issue in AI-enabled grassroots healthcare in China includes the disconnection between healthcare services and AI technology, conflicts with existing healthcare information systems, and low-level repetitive construction of vertical models in the medical field [1][2] - The newly established National AI Application Pilot Base in Hefei aims to address these challenges by creating a government-led, state-owned operation and ecosystem co-construction mechanism, which will provide innovative business models for technology implementation [2] - The pilot base will integrate domestic computing power, research, and ecological resources to lower the innovation and application costs of AI in healthcare, thereby enhancing the overall development landscape [2] Group 2 - The pilot base will establish an efficient data flow system, aggregating 5PB of medical data and integrating 34 specialized medical knowledge bases and 42 multimodal datasets to support grassroots healthcare [2] - It will focus on developing five major medical models and create a toolchain for medical applications, aiming to quickly serve industry scenarios [2] - The initiative will target ten grassroots healthcare service scenarios and eleven public health service scenarios, developing intelligent decision support systems for general practitioners and key population health checks to improve grassroots healthcare service capabilities [2]

Core Insights - The article emphasizes the growing importance of grassroots healthcare in China's medical system, highlighting its role as the first line of defense for public health [1][4][7] - The number of grassroots healthcare institutions in China is projected to reach 1.04 million by 2024, accounting for 95.10% of all medical institutions in the country [1][4] - The revenue of the grassroots healthcare market is expected to grow to 544.5 billion yuan in 2024, with a forecasted increase to 652.2 billion yuan by 2025 [1][7] Grassroots Healthcare Industry Definition and Classification - Grassroots healthcare refers to the primary level of medical care, primarily outpatient services, and includes community health service centers, township hospitals, village clinics, and other medical facilities [2][3] - It serves as the foundation of the healthcare system, providing accessible, comprehensive, and continuous services to the population [2][3] Current Development Status of Grassroots Healthcare - The number of grassroots healthcare institutions has been increasing, with community health service centers and township hospitals making up a significant portion of the total [4][5] - By 2024, community health service centers will number 37,000, and township hospitals will number 33,000, contributing to the overall growth of the sector [4][5] Industry Revenue and Market Growth - The grassroots healthcare market revenue is projected to increase by 48 billion yuan from 2023 to 2024, reaching 544.5 billion yuan [7] - The community health center drug market is expected to reach 107.4 billion yuan in 2024, while the drug market for township hospitals is projected to be 115.8 billion yuan [7] Industry Chain - The upstream of the grassroots healthcare industry includes medical equipment, pharmaceuticals, medical devices, and third-party service providers, while the midstream consists of healthcare service institutions [7][8] - The downstream targets a wide demographic, particularly focusing on the elderly, chronic disease patients, and children [7][8] Policy Environment - The Chinese government has prioritized health development, implementing policies to enhance the grassroots healthcare system, such as optimizing the layout of healthcare institutions [8][9] Competitive Landscape - The competitive landscape includes both domestic and foreign enterprises, with domestic companies holding a larger market share in grassroots healthcare institutions [11][12] - In 2024, foreign enterprises are expected to account for over 20% of the community health center market, while domestic companies dominate township hospitals with a 92.8% share [11][12] Performance Management Strategies - Strengthening grassroots healthcare service capabilities is a strategic focus to address public health challenges and improve resource allocation [13][14] - High-quality performance management is essential for the long-term development of grassroots healthcare, necessitating continuous improvement and optimization of management strategies [14][15]

Core Insights - The 91st National Pharmaceutical Trade Fair (PHARMCHINA) and related expos are being held from November 19 to 21 at the Nanjing International Expo Center, showcasing the scale and influence of China's pharmaceutical and health industry [1] - The exhibition covers nearly 100,000 square meters with over 4,000 booths, featuring more than 2,000 domestic and international health enterprises, highlighting a wide range of products and services [1] - A new "High-Growth Channel Zone" has been established to target the grassroots medical and new retail sectors, providing systematic solutions for companies to expand their channels [1] Industry Events - Over 30 thematic conferences and forums are being held concurrently, covering topics such as commercial circulation, market marketing, policy regulations, traditional Chinese medicine, internationalization, and retail [2] - Special activities focusing on market opportunities, including high-growth channel series and new product launches, are designed to inject innovation into the industry [2] - The "New Product Launch Show" serves as a key platform for introducing innovative products, reflecting the vibrant energy of China's pharmaceutical and health industry [2]

Group 1: Chronic Disease Management in China - The incidence of chronic non-communicable diseases is significantly increasing in China due to rapid economic and social development and an aging population, leading to higher disability rates, mortality rates, and medical costs [1] - The "Healthy China 2030" plan aims to achieve comprehensive chronic disease health management for the entire population and lifecycle by 2030, requiring a series of integrated measures for prevention and control [1] - By 2027, counties (cities, districts) that develop close-knit medical alliances are expected to achieve full-process health management services for chronic diseases at the grassroots level [1] Group 2: COPD and Its Management - Chronic Obstructive Pulmonary Disease (COPD) is a major health concern in China, with nearly 100 million patients, particularly affecting those over 40 years old [3][4] - Early screening, diagnosis, and standardized treatment are crucial for managing COPD, with lung function tests being a key diagnostic method [3][4] - The public awareness of COPD is alarmingly low, with less than 10% of the population aware of the disease, and only about 3% of patients knowing their diagnosis [4] Group 3: Market Dynamics and Growth - The global chronic disease drug market is projected to reach $1.25 trillion in 2024, with China's market expected to reach 685 billion RMB, accounting for 14.3% of the global market [6] - The growth is driven by an aging population, improved early diagnosis rates, and expanded health insurance coverage [6] - The chronic disease drug market in China is characterized by high concentration, high growth, and high innovation, with diabetes drug market growth leading at 14.2% [6] Group 4: AstraZeneca's Strategic Focus - AstraZeneca has been active in the respiratory drug market since the 1990s, introducing various inhalation products for asthma and COPD [7] - The company is undergoing a strategic transformation towards biologics, with a focus on developing innovative treatments for chronic respiratory diseases [7][10] - AstraZeneca aims to enhance accessibility to COPD treatment in grassroots healthcare settings, addressing high misdiagnosis and underdiagnosis rates [8][11] Group 5: Policy and Collaborative Efforts - The Chinese government has implemented policies to improve early screening, diagnosis, and treatment capabilities for chronic respiratory diseases [11] - AstraZeneca is collaborating with local healthcare providers to support the establishment of disease management centers and enhance the capabilities of community health services [8][11] - The company's efforts align with the "Healthy China 2030" initiative, aiming to provide better healthcare services for chronic disease patients [11]

Core Viewpoint - Sichuan Good Doctor Cloud Medical Technology Group Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, with Haitong International and CITIC Securities as joint sponsors [1] Company Overview - Good Doctor Cloud Medical is a leading comprehensive grassroots medical empowerment platform in China, aiming to provide high-quality medical resources to grassroots markets, allowing local residents to access tertiary hospital-level medical services and products [5] - The company ranks second in China's grassroots medical empowerment service industry based on revenue as of 2024 [7] Market Position - As of June 30, 2025, Good Doctor Cloud Medical has directly served over 660,600 grassroots medical terminal customers, including over 389,300 grassroots medical institutions and 271,300 grassroots pharmacies [8] - The company is the only comprehensive empowerment platform in China's grassroots medical industry that utilizes digital intelligence and AI assistance, offering integrated solutions covering testing, diagnosis, medication, and treatment [7][8] Customer Growth - The number of registered grassroots medical terminal customers has grown at a compound annual growth rate (CAGR) of 29.0% from December 31, 2022, to December 31, 2024 [9] - The average monthly paying customer count increased from over 83,800 in 2022 to over 121,900 in 2024, reflecting a CAGR of 20.6% [9] Industry Insights - The grassroots medical industry in China is substantial, consisting of approximately 1.636 million grassroots medical terminals, including about 1.04 million grassroots medical institutions and 291,000 single pharmacies [9] - The market size of China's grassroots medical industry is projected to reach RMB 544.5 billion in 2024, with an expected CAGR of 9.2% from 2024 to 2030, reaching RMB 922 billion by the end of 2030 [9] Financial Performance - For the fiscal years ending June 30, 2023, 2024, and 2025, the company reported revenues of approximately RMB 3.065 billion, RMB 3.264 billion, and RMB 1.891 billion, respectively [10] - The profits for the same periods were RMB 62.48 million, RMB 37.81 million, and RMB 35.77 million, respectively [10]

Group 1 - The event "2025 Most Beautiful Grassroots Doctors Recommendation and Display" has been officially launched to promote respect for medical professionals and enhance grassroots healthcare services [1][2] - Good Doctor Group and Shenyang Qinggong Pharmaceutical Group are key supporters of the event, aiming to create a positive environment for grassroots healthcare and recognize the contributions of grassroots doctors [2][3] - The initiative seeks to establish a platform for professional development and skill enhancement for grassroots doctors, fostering a culture of respect and recognition within society [3][4] Group 2 - Good Doctor Group has been dedicated to grassroots healthcare development, focusing on "caring for public health" and "industry feeding back to public welfare" since its establishment [4] - The company has launched a large-scale public welfare project for training rural doctors, emphasizing a comprehensive training system that includes knowledge empowerment and hardware support [4][5] - Shenyang Qinggong Pharmaceutical aims to enhance grassroots medical capabilities while preserving traditional Chinese medicine, participating in various academic and training activities to support grassroots healthcare [5][6] Group 3 - The selection process for the event includes self-nominations, unit recommendations, and media recommendations, with a final list determined through public opinion screening and field research [5][6] - The event encourages grassroots medical workers to submit their materials for evaluation, with selected individuals invited to an annual summary and awards ceremony [5][6]

Core Points - The event "2024 Most Beautiful Grassroots Doctors Recommendation and Display Activity" was held in Beijing, highlighting the contributions of grassroots medical workers in improving public health [1][2] - The average life expectancy in China has significantly increased, attributed to the dedication of grassroots healthcare workers [2] - The event aims to promote the stories and virtues of grassroots doctors, encouraging more social support for grassroots healthcare initiatives [2][3] Group 1 - The "2024 Most Beautiful Grassroots Doctors Recommendation and Display Activity" was organized by the China Medical News Information Association, with support from People's Health and various pharmaceutical companies [1][3] - Grassroots doctors are recognized as the guardians of public health, and their stories of dedication and compassion are emphasized as deserving of wider recognition [2] - The event included the announcement of 100 recommended grassroots medical workers, showcasing their contributions to community health [3][4] Group 2 - The event featured industry experts and leaders who acknowledged the importance of social support for grassroots healthcare [3] - Future activities will continue to focus on recognizing and supporting grassroots medical workers, with plans for the 2025 annual event already in motion [3][4] - The commitment of companies like Good Doctor Group to support grassroots healthcare through training and development initiatives was highlighted [2]